** Drug and devices maker Johnson & Johnson JNJ.N falls 2.7% to $161.41 premarket
** U.S. bankruptcy judge rejects JNJ's $10 billion proposal to end tens of thousands of lawsuits alleging that its baby powder and other talc products cause ovarian cancer
** This is the third time co's bankruptcy strategy has failed in court
** J&J has been attempting to resolve the lawsuits through subsidiary company's bankruptcy, after two previous bankruptcy attempts failed in other courts
** Leerink Partners says since the bankruptcy plan was dismissed, claimants can continue to proceed with individual trials against co
** Stock gains 14.7% this year, as of last close
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.